DANIEL’S BENLYSTA TREATMENT

Hypothetical patient profile. May not be
representative of all patients.

  • TRANSCRIPT

    DANIEL: I still had protein in my urine and started having butterfly rash. So, my doctor and I discussed about adding BENLYSTA to my treatment. I first got started on BENLYSTA infusions for a couple of months and when my doctor shared that I could switch to the injections at home once a week if I preferred, that was great news; that sounded pretty good to me. He was confident that BENLYSTA could help improve my lupus and lupus nephritis.

    ON-SCREEN TEXT: Daniel’s current therapy: BENLYSTA IV for 8 weeks; 10 mg/kg administered every 2 weeks for the first 3 doses and every 4 weeks thereafter; Switched to BENLYSTA SC* – 200 mg once per week; Mycophenolate mofetil (MMF): 2 g/day orally; Prednisone: 7.5 mg/day; Hydroxychloroquine: 300 mg/day.

    ON-SCREEN TEXT: * Patients with SLE: Administer the first subcutaneous dose 1 to 4 weeks after the last intravenous dose. IV and SC are not to be used concurrently. Patients with lupus nephritis: Transition to subcutaneous therapy can be done any time after the patient completes the first 2 intravenous doses. Administer the first subcutaneous dose 1 to 2 weeks after the last intravenous dose. IV and SC are not to be used concurrently.

    DANIEL: It’s now been a few months since I first started on BENLYSTA, and it seems to be working well. My kidney function has improved, and I’ve been able to lower my steroid dose.

    ON-SCREEN TEXT: Results may vary.

    DANIEL: I appreciate the option of the Autoinjector. And I love the once-weekly dosing with at-home convenience. I’m always running around with the kids, so it’s very comforting to know that I can take my injection at home.

    ON-SCREEN TEXT: Trademarks owned or licensed by GSK. BELVID210026 September 2021.

You may also like

SEE DANIEL’S
DIAGNOSIS STORY
REVIEW DANIEL’S
INITIAL TREATMENT
JOIN US FOR
A LIVE WEBINAR

Hypothetical patient profile. May not be representative of all patients.